Cargando…

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity

PURPOSE: The selective elimination of cancer stem cells (CSCs) in tumor patients is a crucial goal because CSCs cause drug refractory relapse. To improve the current conventional bispecific immune-engager platform, a 16133 bispecific natural killer (NK) cell engager (BiKE), consisting of scFvs bindi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmohl, Jörg U., Felices, Martin, Oh, Felix, Lenvik, Alexander J., Lebeau, Aaron M., Panyam, Jayanth, Miller, Jeffrey S., Vallera, Daniel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654165/ https://www.ncbi.nlm.nih.gov/pubmed/28231426 http://dx.doi.org/10.4143/crt.2016.491

Ejemplares similares

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells
por: Arvindam, Upasana Sunil, et al.
Publicado: (2020)

CD133, Selectively Targeting the Root of Cancer
por: Schmohl, Jörg U., et al.
Publicado: (2016)

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
por: Schmohl, Joerg U., et al.
Publicado: (2016)

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
por: Harwardt, Julia, et al.
Publicado: (2023)

Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
por: Khanna, Vidhi, et al.
Publicado: (2021)

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
por: Vallera, Daniel A., et al.
Publicado: (2021)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2022)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

The role of CD133 in cancer: a concise review
por: Glumac, Paige M., et al.
Publicado: (2018)

A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region
por: Hajduczki, Agnes, et al.
Publicado: (2020)

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022)

Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development
por: Schmohl, Joerg U., et al.
Publicado: (2015)

Silicate Esters of Paclitaxel and Docetaxel: Synthesis, Hydrophobicity, Hydrolytic Stability, Cytotoxicity, and Prodrug Potential
por: Wohl, Adam R., et al.
Publicado: (2014)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
por: Yang, Yan, et al.
Publicado: (2020)

Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization
por: Olsen, Cathrine Elisabeth, et al.
Publicado: (2019)

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies
por: Schmohl, Joerg U., et al.
Publicado: (2018)

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
por: Ojo, Evelyn O., et al.
Publicado: (2019)

The impact of proline isomerization on antigen binding and the analytical profile of a trispecific anti-HIV antibody
por: Masiero, Alessandro, et al.
Publicado: (2020)

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
por: Sanchez-Martinez, Diego, et al.
Publicado: (2018)

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer
por: Kennedy, Philippa R., et al.
Publicado: (2023)

Analysis of [Gossypium capitis-viridis × (G.hirsutum × G.australe)(2)] Trispecific Hybrid and Selected Characteristics
por: Chen, Di, et al.
Publicado: (2015)

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
por: Steinhardt, James J., et al.
Publicado: (2018)

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
por: Pekar, Lukas, et al.
Publicado: (2020)

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
por: Vallera, Daniel A., et al.
Publicado: (2020)

Isolation of CD133+ Liver Stem Cells for Clonal Expansion
por: Rountree, C. Bart, et al.
Publicado: (2011)

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
por: Promsote, Wanwisa, et al.
Publicado: (2023)

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
por: Castoldi, R., et al.
Publicado: (2012)

Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
por: Ravirala, Divya, et al.
Publicado: (2021)

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
por: Abrams, R. E., et al.
Publicado: (2022)

A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies
por: Wang, Bo, et al.
Publicado: (2022)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

Periodic-shRNA molecules are capable of gene silencing, cytotoxicity and innate immune activation in cancer cells
por: Shopsowitz, Kevin E., et al.
Publicado: (2016)

Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer
por: Khanna, Vidhi, et al.
Publicado: (2019)

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
por: Warmuth, Stefan, et al.
Publicado: (2021)

Harnessing novel engineered feeder cells expressing activating molecules for optimal expansion of NK cells with potent antitumor activity
por: Min, Bokyung, et al.
Publicado: (2021)

Cysteine Cathepsins as Regulators of the Cytotoxicity of NK and T Cells
por: Perišić Nanut, Milica, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fffcgr7kvl7me95k33lrha367n